Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate

Pivotal trial of Moderna's H5N1 bird flu jab gets underway

The first volunteers in a large-scale trial of Moderna's mRNA-based vaccine against bird flu have received shots in the UK and US.

Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate

Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / <_apxh3a_a href='https://www.accessnewswire.com/'>ACCESS Newswire / April

Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate (2026-04-21)

CAMBRIDGE, MA/ ACCESS Newswire/ April 21, 2026/ Moderna, Inc. today announced that the first participants in the U.S. and UK have been dosed in a Phase 3 study of the Company's investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018. In December 2025, the Coalition for Epidemic Preparedness Innovations and Moderna announced that CEPI will...

Moderna Begins Phase 3 Trial of mRNA-108 H5 Pandemic Flu Vaccine with 4,000 U.S. Participants

Archyde Moderna has begun dosing participants in a Phase III randomized clinical trial of its mRNA-based H5 pandemic influenza vaccine candidate, mRNA-108, targeting avian influenza A(H5N1) strains with pandemic potential. The ... Read More The post Moderna Begins Phase 3 Trial of mRNA-108 H5 Pandemic Flu Vaccine with 4,000 U.S. Participants appeared first on Archyde.

Moderna initiates phase 3 bird flu vaccine trial

A phase 3 study of Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate has been initiated. Read more about pandemic preparedness.